Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | PREP | P48147 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5038822 | 0.93 | GLA (0.42) | GLAKMT2ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL5551252 | 0.79 | ALDH1A1 (0.43) | CASP3NPC1RAB9ASMN1; SMN2CYP3A4 | |
| SCHEMBL15368459 | 0.79 | PER2 (0.45) | CASP3NPC1RAB9ASMN1; SMN2TSHR | |
| SCHEMBL8082401 | 0.79 | SMN1; SMN2 (0.44) | CASP3NPC1RAB9ASMN1; SMN2CYP2C9 | |
| SCHEMBL5033016 | 0.79 | ALDH1A1 (0.44) | KMT2ANPC1RAB9ATSHR | |
| Hydrochloric Acid SCHEMBL8082404 | 0.78 | SMN1; SMN2 (0.43) | CASP3NPC1RAB9ASMN1; SMN2CYP2C9 | |
| Hydrochloric Acid SCHEMBL8082397 | 0.78 | SMN1; SMN2 (0.43) | CASP3NPC1RAB9ASMN1; SMN2CYP2C9 | |
| SCHEMBL4985094 | 0.76 | CASP3 (0.46) | CASP3NPC1RAB9ASMN1; SMN2CYP2C19 | |
| SCHEMBL4985086 | 0.76 | CASP3 (0.46) | CASP3NPC1RAB9ASMN1; SMN2CYP2C19 | |
| SCHEMBL5059161 | 0.76 | EGFR (0.53) | GLAKMT2ASMN1; SMN2CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1409024-B1 | MACROCYCLIC METAL COMPLEXES AND USE THEREOF FOR PRODUCTION OF CONJUGATES WITH BIOMOLECULES | BAYER SCHERING PHARMA AG (DE) | 2008-08-06 | — | — | EP | disclosed |
| US-20070014725-A1 | Conjugates of macrocyclic metal complexes with biomolecules and their use for the production of agents for NMR diagnosis and radiodiagnosis as well as radiotherapy | SCHERING AG (DE) | 2007-01-18 | — | — | US | disclosed |
| US-7164016-B2 | Macrocyclic metal complexes and their use for the production of conjugates with biomolecules | SCHERING AG (DE) | 2007-01-16 | — | — | US | disclosed |
| US-20070009442-A1 | Macrocyclic metal complexes and their use for the production of conjugates with biomolecules | SCHERING AG (DE) | 2007-01-11 | — | — | US | disclosed |
| EP-1450864-A2 | CONJUGATES OF MACROCYCLIC METAL COMPLEXES WITH BIOMOLECULES AND THE UTILIZATION THEREOF FOR PRODUCING AGENTS FOR USE IN NMR DIAGNOSIS AND RADIODIAGNOSIS AND RADIOTHERAPY | Schering AG (DE) | 2004-09-01 | — | — | EP | disclosed |
| EP-1409024-A1 | MACROCYCLIC METAL COMPLEXES AND USE THEREOF FOR PRODUCTION OF CONJUGATES WITH BIOMOLECULES | Schering AG (DE) | 2004-04-21 | — | — | EP | disclosed |
| US-20030206865-A1 | Conjugates of macrocyclic metal complexes with biomolecules and their use for the production of agents for NMR diagnosis and radiodiagnosis as well as radiotherapy | SCHERING AG (DE) | 2003-11-06 | — | — | US | disclosed |
| US-20030108486-A1 | Macrocyclic metal complexes and their use for the production of conjugates with biomolecules | SCHERING AG (DE) | 2003-06-12 | — | — | US | disclosed |
| WO-2003013617-A2 | CONJUGATES OF MACROCYCLIC METAL COMPLEXES WITH BIOMOLECULES AND THE UTILIZATION THEREOF FOR PRODUCING AGENTS FOR USE IN NMR DIAGNOSIS AND RADIODIAGNOSIS AND RADIOTHERAPY | SCHERING AG (DE) | 2003-02-20 | — | — | WO | disclosed |
| WO-2003009874-A1 | MACROCYCLIC METAL COMPLEXES AND USE THEREOF FOR PRODUCTION OF CONJUGATES WITH BIOMOLECULES | SCHERING AG (DE) | 2003-02-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030108486-A1 | Macrocyclic metal complexes and their use for the production of conjugates with biomolecules | CA13, MPI, CA14 | CASP3 2621/4885GLA 1919/4885PREP 1804/4885 |
| US-20070014725-A1 | Conjugates of macrocyclic metal complexes with biomolecules and their use for the production of agents for NMR diagnosis and radiodiagnosis as well as radiotherapy | CA13, CA14, CA12 | CASP3 2136/4885GLA 1698/4885PREP 2156/4885 |
| US-20030206865-A1 | Conjugates of macrocyclic metal complexes with biomolecules and their use for the production of agents for NMR diagnosis and radiodiagnosis as well as radiotherapy | CA13, CA14, CA12 | CASP3 2136/4885GLA 1698/4885PREP 2156/4885 |
| US-20070009442-A1 | Macrocyclic metal complexes and their use for the production of conjugates with biomolecules | CA13, MPI, CA14 | CASP3 2621/4885GLA 1919/4885PREP 1804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.